What ORIC Pharmaceuticals (ORIC)'s Cancer Research UK Partnership Means For Shareholders

• ORIC Pharmaceuticals reported that Cancer Research UK has agreed to fully fund, sponsor, design and run early clinical development of ORIC-259, a potential first in class CIP2A targeted cancer therapy, with ORIC retaining an option to reacquire rights after Phase 1/2 data.
• This collaboration shifts early development costs and execution risk for ORIC-259 to Cancer Research UK while preserving upside for ORIC Pharmaceuticals through future milestones and royalties.
• We will now look at how ORIC Pharmaceuticals' investment narrative could shift as Cancer Research UK funds early ORIC-259 development.

Scan how ORIC Pharmaceuticals fits into the broader hunt for funded, high-upside stories by comparing it with 20 high quality undiscovered gems that analysts have already filtered for strong fundamentals.

ORIC Pharmaceuticals Investment Narrative Recap

To own ORIC Pharmaceuticals, you need to believe its pipeline in metastatic prostate cancer and targeted lung cancer can eventually turn today’s research spend into meaningful commercial products. The new Cancer Research UK partnership adds a separate CIP2A asset, ORIC-259, without stretching near term cash, so the core story still sits with rinzimetostat and enozertinib.

The most important near term catalyst remains clean, differentiated data from ongoing rinzimetostat and enozertinib studies that justify progressing into and through Phase III. The biggest risk is still clinical or class safety issues, or delays that extend timelines and raise financing pressure, especially given ORIC Pharmaceuticals is loss making with no current revenue.

The Cancer Research UK agreement matters most because it lets ORIC Pharmaceuticals keep its existing US$388m cash runway focused on late stage trials such as Himalayas 1 for rinzimetostat and the planned Phase III for enozertinib. Early ORIC 259 work moves off balance sheet while ORIC retains an option to bring it back after Phase 1/2 data.

With no recent company announcements beyond this alliance, catalysts still cluster around rinzimetostat plus darolutamide outcomes in metastatic castration resistant prostate cancer and enozertinib’s CNS activity in EGFR exon 20 and atypical NSCLC. If those programs hit setbacks or timing slips, the operational benefit of Cancer Research UK funding on ORIC 259 would not offset weaker visibility on the lead assets.

ORIC Pharmaceuticals' current forecasts point to revenue of US$24.7 million and earnings of US$4.3 million by 2029, off a base of no revenue and a current loss of US$140.4 million. This implies yearly top line growth from zero and an earnings swing of about US$144.7 million if analysts are directionally correct on the move from losses to profits.

Uncover how ORIC Pharmaceuticals' fair value indicates a 72% potential upside to its current price, which could narrow quickly if sentiment around ORIC Pharmaceuticals shifts.

Exploring Other Perspectives

One optimistic twist in the alternate ORIC Pharmaceuticals story is the potential for enozertinib partnering. Bullish analysts were already modelling about US$41.5 million of revenue and US$7.2 million of earnings in 2029 before this Cancer Research UK news, which shows how far expectations can stretch. Use that spread to check your own view, then explore other forecasts as well.

Explore 3 other ORIC Pharmaceuticals fair value estimates, including one that suggests as much as 261% upside from the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ORIC Pharmaceuticals research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for ORIC Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ORIC Pharmaceuticals' overall financial health at a glance.

Looking For More Investment Ideas Beyond ORIC Pharmaceuticals?

Once you have a view on ORIC Pharmaceuticals, it often helps to benchmark that thesis against other opportunities using the Simply Wall St Screener, so you can see where risk, balance sheet strength and valuation line up with your own comfort zone.

• If capital preservation matters most, check out a set of 31 resilient stocks with low risk scores that may better match a cautious approach.
• For investors who care about resilience, review a list of solid balance sheet and fundamentals (25 results) and see which businesses keep financial footing front and centre.
• Income focused readers can scan a group of 8 dividend fortresses that combine yield with market listed liquidity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com